These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10510110)

  • 1. Comorbidity in patients with prostate cancer and its relevance to treatment choice.
    Post PN; Kil PJ; Hendrikx AJ; Janssen-Heijnen ML; Crommelin MA; Coebergh JW
    BJU Int; 1999 Oct; 84(6):652-6. PubMed ID: 10510110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there age bias in the treatment of localized prostate carcinoma?
    Alibhai SM; Krahn MD; Cohen MM; Fleshner NE; Tomlinson GA; Naglie G
    Cancer; 2004 Jan; 100(1):72-81. PubMed ID: 14692026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trend and variation in treatment of localized prostate cancer in the southern part of The Netherlands, 1988-1996. Regional Study Group for Urological Oncology IKZ, Eindhoven.
    Post PN; Kil PJ; Hendrikx AJ; Poortmans PM; Crommelin MA; Coebergh JW
    Eur Urol; 1999 Sep; 36(3):175-80. PubMed ID: 10449998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study.
    Houterman S; Janssen-Heijnen ML; Verheij CD; Kil PJ; van den Berg HA; Coebergh JW
    Prostate Cancer Prostatic Dis; 2006; 9(2):179-84. PubMed ID: 16534509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
    Nguyen PL; Chen MH; Hoffman KE; Chen RC; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV
    BJU Int; 2012 Jul; 110(2):201-5. PubMed ID: 22085233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders.
    Litwiller SE; Djavan B; Klopukh BV; Richier JC; Roehrborn CG
    Urology; 1995 May; 45(5):813-22. PubMed ID: 7747373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996.
    Coebergh JW; Janssen-Heijnen ML; Post PN; Razenberg PP
    J Clin Epidemiol; 1999 Dec; 52(12):1131-6. PubMed ID: 10580775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.
    Kastner C; Armitage J; Kimble A; Rawal J; Carter PG; Venn S
    Prostate Cancer Prostatic Dis; 2006; 9(3):270-4. PubMed ID: 16770340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study.
    Houterman S; Janssen-Heijnen ML; Hendrikx AJ; van den Berg HA; Coebergh JW
    Crit Rev Oncol Hematol; 2006 Apr; 58(1):60-7. PubMed ID: 16213153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.
    Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ
    Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
    van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
    BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
    Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
    Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy.
    Froehner M; Litz R; Manseck A; Hakenberg OW; Leike S; Albrecht DM; Wirth MP
    Urol Int; 2001; 67(4):283-8. PubMed ID: 11741129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Comorbidity, Age, and Radical Surgical Therapy for Prostate Cancer, Bladder Cancer, and Renal Cell Carcinoma.
    Adejoro O; Alishahi A; Konety B
    Urology; 2016 Nov; 97():130-137.e1. PubMed ID: 27397095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of practicing urologists: robotic versus open radical prostatectomy.
    Lee EK; Baack J; Duchene DA
    Can J Urol; 2010 Apr; 17(2):5094-8. PubMed ID: 20398448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity.
    Alibhai SM; Leach M; Tomlinson G; Krahn MD; Fleshner N; Holowaty E; Naglie G
    J Natl Cancer Inst; 2005 Oct; 97(20):1525-32. PubMed ID: 16234566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient comorbidity is associated with conservative treatment of localized prostate cancer.
    Jespersen CG; Nørgaard M; Jacobsen JB; Borre M
    Scand J Urol; 2015; 49(5):366-70. PubMed ID: 25903072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life after radical prostatectomy depends on patient's age but not on comorbidities.
    Herkommer K; Schmid SC; Schulwitz H; Dinkel A; Klorek T; Hofer C; Ehrl D; Blaser R; Gschwend JE; Kron M
    Urol Oncol; 2015 Jun; 33(6):266.e1-7. PubMed ID: 25847625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which patients are at the highest risk of dying from competing causes ≤ 10 years after radical prostatectomy?
    Froehner M; Koch R; Litz RJ; Hakenberg OW; Wirth MP
    BJU Int; 2012 Jul; 110(2):206-10. PubMed ID: 22044591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.